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Whole genome sequencing of 
drug resistant Mycobacterium 
tuberculosis isolates from a high 
burden tuberculosis region of north 
West pakistan
Abdul Jabbar1,2*, Jody E. Phelan  3, Paola Florez de Sessions4, Taj Ali Khan2, Hazir Rahman5, 
Sadiq Noor Khan1, Daire M. Cantillon6, Leticia Muraro Wildner6, Sajid Ali7, Susana Campino3, 
Simon J. Waddell6,9 & Taane G. Clark  3,8,9*
Tuberculosis (TB), caused by Mycobacterium tuberculosis bacteria, is a leading infectious cause of 
mortality worldwide, including in Pakistan. Drug resistant M. tuberculosis is an emerging threat for 
TB control, making it important to detect the underlying genetic mutations, and thereby inform 
treatment decision making and prevent transmission. Whole genome sequencing has emerged as 
the new diagnostic to reliably predict drug resistance within a clinically relevant time frame, and its 
deployment will have the greatest impact on TB control in highly endemic regions. To evaluate the 
mutations leading to drug resistance and to assess for evidence of the transmission of resistant strains, 
81 M. tuberculosis samples from Khyber Pakhtunkhwa province (North West Pakistan) were subjected 
to whole genome sequencing and standard drug susceptibility testing for eleven anti-TB drugs. We 
found the majority of M. tuberculosis isolates were the CAS/Delhi strain-type (lineage 3; n = 57; 70.4%) 
and multi-drug resistant (MDR; n = 62; 76.5%). The most frequent resistance mutations were observed 
in the katG and rpoB genes, conferring resistance to isoniazid and rifampicin respectively. Mutations 
were also observed in genes conferring resistance to other first and second-line drugs, including in pncA 
(pyrazinamide), embB (ethambutol), gyrA (fluoroquinolones), rrs (aminoglycosides), rpsL, rrs and giB 
(streptomycin) loci. Whilst the majority of mutations have been reported in global datasets, we describe 
unreported putative resistance markers in katG, ethA (ethionamide), gyrA and gyrB (fluoroquinolones), 
and pncA. Analysis of the mutations revealed that acquisition of rifampicin resistance often preceded 
isoniazid in our isolates. We also observed a high proportion (17.6%) of pre-MDR isolates with 
fluoroquinolone resistance markers, potentially due to unregulated anti-TB drug use. Our isolates were 
compared to previously sequenced strains from Pakistan in a combined phylogenetic tree analysis. The 
presence of lineage 2 was only observed in our isolates. Using a cut-off of less than ten genome-wide 
mutation differences between isolates, a transmission analysis revealed 18 M. tuberculosis isolates 
clustering within eight networks, thereby providing evidence of drug-resistant TB transmission in the 
Khyber Pakhtunkhwa province. Overall, we have demonstrated that drug-resistant TB isolates are 
circulating and transmitted in North West Pakistan. Further, we have shown the usefulness of whole 
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genome sequencing as a diagnostic tool for characterizing M. tuberculosis isolates, which will assist 
future epidemiological studies and disease control activities in Pakistan.
Tuberculosis (TB), caused by Mycobacterium tuberculosis bacteria, is a global public health problem responsible for 10 
million new cases and 1.6 million deaths worldwide in 20171. M. tuberculosis drug resistance is making disease control 
more difficult, with 490,000 TB cases identified as resistant to both rifampicin (RIF) and isoniazid (INH) (multi-drug 
resistant, “MDR-TB”) in 2017. Five countries India, China, Indonesia, Philippines and Pakistan contribute more than 
half (56%) of the total TB global burden1. Pakistan has an estimated 518,000 TB cases each year, including ~15,000 
MDR-TB patients. The estimated proportion of MDR-TB in Pakistan is ~4% in new cases and ~17% in patients 
who have previously been treated2. Khyber Pakhtunkhwa province (population size 35.5 million; 11.9% of the total 
population) is situated in North West Pakistan and shares a border with Afghanistan. The province contains the 
semi-autonomous federally administered tribal areas inhabited by the Pashtun people. The province has been affected 
by recent military action and accommodates the majority of the 1.4 million Afghan refugees currently in Pakistan. 
Khyber Pakhtunkhwa has an estimated 270 TB cases per 100,000 population2. Sputum smear microscopy is used as a 
primary screening test for the diagnosis of TB at local clinics, while GeneXpert MTB/RIF assays are employed for the 
rapid detection of rifampicin resistant TB at the district level3. Laboratory culture and drug susceptibility testing are 
available at the provincial level. Treatment of drug-susceptible TB is for six months, while for MDR-TB it is nearly two 
years4. M. tuberculosis may become extensively drug resistant (XDR-TB), which is MDR-TB with additional resistance 
to fluoroquinolones (e.g. ofloxacin) and at least one of the second line injectable aminoglycoside drugs (e.g. kanamy-
cin, amikacin or capreomycin)5. In Pakistan, of all TB cases, ~5% are MDR-TB, and of these, ~5% are XDR-TB6,7.
The global emergence and rise in the prevalence of MDR-TB and XDR-TB cases in the past decade has made 
it imperative to detect drug resistance rapidly and accurately8. Drug resistance in M. tuberculosis is almost exclu-
sively due to mutations (including single nucleotide polymorphisms (SNPs), insertions and deletions (indels)) 
in genes coding for drug-targets or drug-converting enzymes9,10. Putative compensatory mechanisms have been 
described to overcome fitness impairment that arise during the accumulation of resistance conferring muta-
tions9,11. Efflux pumps are also thought to have a role in resistance9,12. M. tuberculosis culture and drug suscepti-
bility testing is the gold standard technique, but this can take several weeks. The development of molecular tests, 
such as GeneXpert and line probe assays, can be used to detect M. tuberculosis directly from clinical samples 
and identify some mutations underlying MDR-TB. Whole genome sequencing (WGS) provides higher resolu-
tion9, and can be used to identify SNPs and indels in loci linked to drug resistance13. Known and putative mark-
ers of drug resistance have been identified using phylogenetic tree-based and genome-wide association study 
approaches9. Libraries of informative resistance mutations are leading to the development of informatic tools to 
rapidly profile samples for their drug susceptibility to aid clinical decision making10,14.
The M. tuberculosis complex has seven lineages that are endemic in different locations around the globe, leading 
to the hypothesis that the strain-types are specifically adapted to people of different genetic backgrounds15,16. The line-
ages vary in their geographic distribution and spread, with lineage 2 being particularly mobile with evidence of recent 
spread from Asia to Europe and Africa15. Lineage 4 is common in Europe and southern Africa, with regions of high TB 
incidence and high levels of HIV co-infection. Lineage 3, including Central Asian (CAS) strains, are common in South 
Asia. The lineages may vary in propensity to transmit and severity of disease16, but there is considerable inter-strain var-
iation within lineages12. A set of SNPs has been identified that can be used to barcode sub-lineages15, leading to infor-
matic tools that position sequenced samples within a global phylogeny17. Similarly, SNPs have been used to construct 
transmission networks, where samples from different individuals that have near identical genome sequences are most 
likely to be due to a transmission event. Analysis of genome-wide SNPs characterized in M. tuberculosis DNA sourced 
from a highly endemic TB region in Malawi has shown striking differences by lineage in the proportion of disease due 
to recent transmission and in transmissibility, highest in lineage2 (East-Asian), and lowest in lineage1 (Indo-Oceanic)18.
There have been few WGS TB studies in Pakistan, and none have focused on the tribal and migrant popu-
lations of the North West. One study characterized drug resistance mutations across 42 XDR-TB isolates from 
the Aga Khan University (Karachi) strain bank (years 2004–2009), which were sourced from 4 provinces (Sindh 
(21), Punjab (16), Khyber Pakhtunkhwa (4), Baluchistan (1))19. These isolates were predominantly CAS lineage 
3 strains19, in keeping with previous genotyping-based studies20. The Karachi study found that most rifampicin 
resistance was attributable to SNPs in the rpoB hot-spot region, and isoniazid resistance was most commonly 
associated with the katG (codon 315) and inhA (S94A) mutations. Beyond MDR-TB, the study found that only 
43% of pyrazinamide could be explained by pncA SNPs, fluoroquinolone resistance was mostly explained by 
gyrA (91–94 codon) mutations, and resistance to aminoglycoside injectables was associated with rrs mutations. 
The concordance between phenotypic and genotypic testing was highest for rifampicin and isoniazid (>90%), 
and lowest for pyrazimamide (<50%)19. Follow-up work with the XDR-TB isolates revealed SNPs in efflux pump 
genes, which may influence drug resistance12. In our study, we performed WGS on 81 drug resistant M. tubercu-
losis from the Khyber Pakhtunkhwa province, which is endemic for TB across its tribal and migrant populations, 
but where public health surveillance systems are not strong. We characterize the underlying M. tuberculosis resist-
ance mutations, identifying novel drug-resistance conferring mutations and, in a combined Pakistan WGS data 
analysis, reveal potential MDR-TB transmission chains. Our methods and findings will assist future WGS and 
drug resistance mapping studies and inform disease control efforts in Pakistan and neighbouring Afghanistan.
Materials and Methods
The samples and whole genome sequencing. A total of 81 predominantly drug resistant isolates were 
randomly selected from 8,220 archived M. tuberculosis samples collected between June 2016 and June 2017 at 
the Provincial TB Reference Laboratory, Hayatabad Medical Complex Peshawar, Khyber Pakhtunkhwa prov-
ince of Pakistan. Demographic data (e.g. age, sex) were collected from each TB patient that contributed sputum, 
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alongside drug regimen and treatment outcome. The sputum samples were digested and decontaminated using 
the N-acetyl-L-cysteine sodium hydroxide (NALC-NaOH) method, and the M. tuberculosis cultured in modified 
7H9 Middlebrook media in the Mycobacterium Growth Indicator Tube (MGIT) system. Positive cultures were 
confirmed using the BD MGIT TBc identification (TBc ID) or Capilia chromatographic tests21. All laboratory 
work involving the culture of live bacteria (from sputum) was performed under category level 3 bio-containment 
facilities and protocols. DNA samples were extracted using the CTAB method22. Before sequencing, the DNA 
was RNase-treated, quantified and quality assessed by NanoDrop One spectrophotometer and Qubit 2.0 fluo-
rometer using the Qubit dsDNA BR Assay Kit (ThermoFisher Scientific). The samples were sequenced on the 
Illumina MiSeq and HiSeq2000 platforms using 200 bp paired end runs at the London School of Hygiene and 
Tropical Medicine and Genome Institute of Singapore genomic facilities. The confirmed M. tuberculosis MGIT 
cultured isolates underwent standard drug susceptibility testing against isoniazid (critical concentration 0.1 µl/
ml), rifampicin (1.0 µl/ml), ethambutol (5.0 µl/ml), streptomycin (1.0 µl/ml), moxifloxacin (2.5 μg/ml), amikacin 
(1.0 μg/ml), kanamycin (2.5 μg/ml), capreomycin (2.5 μg/ml) and ofloxacin (2.0 μg/ml). Pyrazinamide suscepti-
bility testing was performed using an established protocol23.
Bioinformatic analysis. Sequence reads were inspected using fastQC (www.bioinformatics.babraham.
ac.uk/projects/fastqc/) as a primary assessment of data quality. The reads were trimmed using trimmomatic soft-
ware24 to remove low quality sequences, and then mapped against the H37Rv reference genome (AL123456) 
using the BWA-mem alignment package25. SNPs were called using the BCF/VCF software suite26, and those in 
non-unique regions of the genome (e.g. ppe genes) were excluded. SNPs were converted into a FASTA format 
alignment, which was used as input to RAxML (v8.0.0) software27 to reconstruct a phylogenetic tree. The tree 
was annotated and visualized using iTOL28. Drug resistance profiles and lineages were predicted in-silico using 
TB-Profiler (v2.4)10,14, using a library of established mutations (https://github.com/jodyphelan/tbdb). SpolPred 
software29 was used to in-silico predict spoligotypes.
Ethical approval. This study was approved by the ethical committees of the Kohat University of Science 
and Technology, Kohat, and the Provincial TB Reference Lab, Hayatabad Medical Complex Peshawar, Pakistan. 
Informed consent was given by all patients who contributed sputum.
Results
Clinical isolates and phylogeny. The 81 M. tuberculosis were predominantly sourced from TB hospi-
tals and clinics in Peshawar, the largest city of Khyber Pakhtunkhwa province (Table 1; Supplementary Fig. 1). 
The patients contributing M. tuberculosis samples had a median age of 28, and there was gender parity (male: 
n = 41, 50.6%). In-silico predictions of resistance across the eleven anti-TB drugs revealed that the majority were 
MDR-TB (n = 62; 76.5%), with the others being pan-susceptible (n = 1; 1.2%), XDR-TB (n = 5; 6.2%) and non-
MDR-/XDR-TB drug-resistant (n = 13; 16.0%). There were high levels of rifampicin (93.8%), isoniazid (84.0%), 
ethambutol (75.3%) and fluoroquinolone (63.0%) drug resistance and low levels of aminoglycoside resistance 
(3.7%). Mapping of the raw M. tuberculosis sequence data (Supplementary Table 1) led to high average genome-
wide coverage across the clinical isolates (median: 227-fold; range: 74- to 288-fold). Across the isolates, 18,667 
unique SNPs were identified; a high proportion (37%) of these were observed in single isolates. Isolates were 
classified predominantly into lineage 3 (CAS) strain types (70.4%) (Table 1), but lineages 1 (3.7%), 2 (11.1%; all 
Beijing strain-types) and 4 (14.8%) were also present. As expected, these lineages form clusters in a genome-wide 
SNP-based phylogenetic tree (Fig. 1; Supplementary Fig. 2).
Mutations underlying drug-resistance. Resistance mutations14 were assessed and compared to the 
phenotypic drug susceptibility test results for 11 anti-TB drugs. There was perfect concordance between the 
phenotypic result and in-silico prediction for rifampicin resistance. This resistance was predominantly associ-
ated with known mutations at codon 450 in the rpoB gene (conferred by 3 mutations; in 59/76 resistant iso-
lates; including S450L 56/76; Table 2; Supplementary Table 2), but also ten other putative mutations in the 
rifampicin-resistance-determining region (RRDR) and two mutations outside this region (L430R, L430P). A 
minority of rifampicin resistant isolates had putative compensatory rpoC mutations (I491T 7/76 (all Beijing), 
I885V 1/76 (CAS/Delhi)), which all had rpoB S450L background mutations. Mutations identified in the katG gene 
(S315T 61/68) and the Rv1482c–fabG1 intergenic region (7/68) were most likely to be responsible for isoniazid 
resistance, but additional mutations in oxyR’-ahpC (1/68) and katG (5/68) were found in single isolates (Table 2; 
Supplementary Table 2). The phenotypic results and in-silico predictions were identical except for three isolates. 
These isolates had distinct previously uncharacterized frameshift mutations in the katG gene (Supplementary 
Table 2), most likely leading to resistance due to a loss of function of the isoniazid activating enzyme.
Ethambutol resistance was conferred by mutations in the embCAB operon, including embB (M306 45/61; 
G497 9/61; G406 7/61). By assuming the laboratory phenotypic test result as the gold standard, the sensitiv-
ity of the in-silico prediction was high (97.2%), but the specificity was much lower (42.2%). This differential is 
most likely due to the large number of isolates predicted to be resistant based on the presence of mutations in 
codon 306 of the embB gene (n = 10). These mutations have been shown to confer resistance, albeit at a moderate 
level30. Pyrazinamide resistance is typically associated with the pncA gene, and we identified 31 non-synonymous 
mutations in that locus, with the most frequent being pncA-Rv2044c −11A > G (4/43), V180P (4/43), and H71A 
(3/43). The comparison of the pncA allele frequencies in our study to those in a global WGS dataset14 revealed 
four indels and three SNPs to be novel (Supplementary Fig. 3, Supplementary Table 2). Further, one isolate con-
tained a 405 bp deletion that removed a large proportion of the pncA gene (Supplementary Fig. 3, Supplementary 
Table 2). Mutations in other genes associated with pyrazinamide resistance (rpsA and panD) were not detected. 
There was a moderate level of concordance between the phenotypic drug susceptibility test results and in-silico 
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predictions for pyrazinamide (sensitivity 74.1%, specificity 70.4%). However, this discrepancy may be explained 
by the known difficulty in performing drug susceptibility testing for pyrazinamide resistance and its resulting 
high variability.
As expected for the samples selected for sequencing, drug resistance conferring mutations were also detected 
to second line anti TB drugs. Streptomycin resistance is typically related to mutations in gid, rpsL and rrs loci, 
which are related to low, low and intermediate, and high levels of resistance, respectively9. The mutations occur-
ring in the gid gene were a frameshift (102del, 6/42) and A80P (2/42). The most common resistance conferring 
mutations were in the rrs (514a > c; 12/42) and rpsL (L43A 12/42) genes. One of the isolates had mutations in 
both gid (G352 → GC) and rpsL (K88R). Resistance to ethionamide is associated with the ethA locus, and nine 
mutations were identified in that gene, each present in single resistant isolates (Supplementary Table 2). Eight of 
these mutations were not present in a large global resistance database14, and may be novel resistance conferring 
mutations. The most frequent mutation was in the fabG1 promoter region (−15C > T; 7/15), which is also asso-
ciated with isoniazid resistance9 (Table 2).
Resistance to second-line fluoroquinolones and aminoglycosides. Mutations in the gyrA and gyrB 
loci associated with fluoroquinolone resistance were observed. The majority of which were in gyrA (D94 40/51; 
S91P 5/51; A90V 4/51). Other mutations in gyrA (1/51) and gyrB (3/51) were present in single isolates, but absent 
in a global resistance database14, suggesting that these may be novel fluoroquinolone resistance-conferring muta-
tions. Two isolates had multiple resistance mutations in the gyrA gene (A94G-S91P and A90V-DA94G). The 
consistency between the drug susceptibility phenotypic results and in-silico predictions was variable for the two 
fluoroquinolones tested (moxifloxacin and ofloxacin). Whilst the sensitivities for both fluoroquinolones were 
100%, the specificities were dissimilar (ofloxacin 85.7%; moxifloxacin 40.8%), which may be explained by dif-
ferences in the critical concentration used for the drug susceptibility testing (moxifloxacin 2.5 μg/ml, ofloxacin 
2.0 μg/ml).
Characteristic N %
Male 41 50.6
Age (in years)
   5–14 4 4.9
   15–24 24 29.6
   25–54 40 49.4
   >=55 13 16.1
Location*
   PMDT Peshawar 37 45.7
   PMDT D.I.Khan 17 21.0
   PMDT Abbottabad 13 16.0
   PMDT Swat 6 7.4
   PRL Peshawar 3 3.7
   KTH Peshawar 2 2.5
   HMC Peshawar 2 2.5
   MMC Mardan 1 1.2
Lineages**
   1 3 3.7
   2 9 11.1
   3 57 70.4
   4 12 14.8
Drug resistance***
   Rifampicin 76 93.8
   Isoniazid 68 84.0
   MDR-TB 67 82.7
   Ethambutol 61 75.3
   Streptomycin 40 49.4
   Ethionamide 15 18.5
   Fluoroquinolones 51 63.0
   Aminoglycosides 3 3.7
   XDR-TB 5 6.2
Table 1. Mycobacterium tuberculosis samples (N = 81). *HMC = Hayatabad Medical Complex, 
D.I.Khan = Dera Ismail Khan, KTH = Khyber Teaching Hospital, MMC = Mardan Medical Complex, 
PMDT = Programmatic Management of Drug Resistant TB, PRL = Provincial TB Reference Laboratory; **all 
lineage 3 strains are the CAS/Delhi strain-type; ***from in-silico prediction using TB-Profiler (v2.4)14, where 
MDR-TB = multi-drug resistant TB, XDR-TB = extensively drug resistant TB.
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Resistance across the aminoglycoside injectable drugs was associated with the rrs A1401G, which was linked 
with amikacin (3/3), capreomycin (3/3) and kanamycin (3/5) resistance. Kanamycin resistance was also observed 
with a mutation in the eis locus (−14C > T, 2/5). This mutation has been found to be related to low levels of kan-
amycin resistance9 but not associated with resistance to other aminoglycosides. A number of discrepancies were 
Figure 1. Phylogenetic tree of M. tuberculosis strains (n = 81), with their lineages and drug resistance profiles. 
The phylogenetic tree was created using a maximum likelihood approach implemented in RAxML27. The tree 
was annotated using iTOL28. The first vertical band to the right of the tree denotes the lineage. The second 
vertical band denotes the drug resistance phenotype. The circles show the drug resistance profiles, with filled 
circles representing the presence of a resistance mutation. Some profiles are examples of isolates that are both 
pre-MDR and fluoroquinolone resistant. MDR = multi-drug resistant TB, XDR = extensively drug resistant TB; 
drug resistant = non-MDR/XDR resistant; based on drug susceptibility testing and TB-Profiler prediction14.
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observed between the phenotypic test results and in-silico predictions for resistance. Three isolates had a resistant 
drug susceptibility test result for amikacin but did not have any known resistance mutations. Of these, one isolate 
did not have any mutations in known resistance genes, but the other two isolates had a (878 g > a) mutation in the 
rrs gene. This mutation has previously been reported to confer resistance to capreomycin31, and therefore poten-
tially amikacin resistance too. Two isolates had resistant drug susceptibility test results for kanamycin but did not 
have any mutations in known resistance genes.
The presence of fluoroquinolone resistance mutations (n = 51; 63.0%) was overwhelmingly more common 
than aminoglycoside (amikacin/capreomycin) resistance mutations (n = 3; 3.7%), which is in contrast to other 
settings where resistance to second-line injectables was more common32. Inspection of the in-silico predictions 
revealed a significant proportion of isolates with fluoroquinolone resistance mutations to be pre-MDR-TB (n = 9; 
17.6%). In particular, five isolates were resistant to fluoroquinolones and rifampicin but not isoniazid, one was 
resistant to fluoroquinolones and isoniazid but not rifampicin, and three were resistant to fluoroquinolones but 
sensitive to both rifampicin and isoniazid.
Mutations in efflux pumps. Across the 81 isolates, we characterized fifty-five mutations in thirteen 
efflux pump genes (Rv0194, Rv1217, Rv1218, drrA, drrB, Rv1258, Rv1634, Rv2688, Rv1273, Rv1819, Rv1458, 
Rv1877 and Rv1250) (Supplementary Table 3). These mutations included twelve identified in previous work in 
Pakistan12. Mutation variants were observed in all thirteen efflux pump genes, with both SNPs and indels present 
(Supplementary Table 3). Mutations in efflux genes were present in both susceptible and drug-resistant isolates, 
demonstrating that their potential role in resistance may be complex, and mechanisms may involve transcrip-
tional or epigenetic effects that we did not consider.
Evidence of transmission. We combined our study WGS data (n = 81) with those from a published Karachi 
study19 (n = 42). Potential transmission clusters were found by calculating the pairwise SNP distance between the 
Drug Gene Mutation Resistant* (%)
Global frequency 
resistant (%)**
Isoniazid katG Ser315Thr 61/68 (89.7) 4071/5423 (75.1)
Rifampicin rpoB Ser450Leu 56/76 (73.7) 2975/4618 (64.4)
Fluoroquinolones gyrA Asp94Gly 26/51 (51.0) 153/527 (29.0)
Ethambutol embB Met306Ile 20/61 (32.8) 567/2662 (21.3)
Ethambutol embB Met306Val 15/61 (24.6) 840/2662 (31.6)
Streptomycin rpsL Lys43Arg 12/42 (28.6) 649/1408 (46.1)
Streptomycin rrs r.514a > c 12/42 (28.6) 128/1408 (9.1)
Ethambutol embB Met306Leu 10/61 (16.4) 34/2662 (1.3)
Fluoroquinolones gyrA Asp94Ala 9/51 (17.7) 62/527 (11.8)
Ethionamide fabG1 −15C > T 7/15 (46.7) 190/347 (54.8)
Isoniazid fabG1 −15C > T 7/68 (10.3) 877/5423 (16.2)
Rifampicin rpoC Ile491Thr 7/76 (9.2) 91/4618 (2.0)
Streptomycin gid c.102_102del 6/42 (14.3) 12/1408 (0.9)
Ethambutol embB Gln497Arg 5/61 (8.2) 207/2662 (7.8)
Fluoroquinolones gyrA Ser91Pro 5/51 (9.8) 40/527 (7.6)
Pyrazinamide pncA −11A > G 4/43 (9.3) 77/1946 (4.0)
Fluoroquinolones gyrA Ala90Val 4/51 (7.8) 152/527 (28.8)
Rifampicin rpoB Asp435Val 4/76 (5.3) 296/4618 (6.4)
Ethambutol embB Gly406Ala 4/61 (6.6) 318/2662 (12.0)
Pyrazinamide pncA Val180Phe 4/43 (9.3) 4/1946 (0.2)
Ethambutol embA −12C > T 3/61 (4.9) 115/2662 (4.3)
Fluoroquinolones gyrA Asp94Asn 3/51 (5.9) 22/527 (4.2)
Ethambutol embB Gln497Lys 3/61 (4.9) 20/2662 (0.8)
Ethambutol embB Gly406Asp 3/61 (4.9) 75/2662 (2.8)
Ethambutol embB Gly406Ser 3/61 (4.9) 37/2662 (1.4)
Rifampicin rpoB His445Tyr 3/76 (4.0) 230/4618 (5.0)
Pyrazinamide pncA His71Arg 3/43 (7.0) 2/1946 (0.1)
Streptomycin rpsL Lys88Arg 3/42 (7.1) 104/1408 (7.4)
Amikacin rrs 1401a > g 3/3 (100) 291/349 (83.4)
Capreomycin rrs 1401a > g 3/3 (100) 307/404 (76.0)
Kanamycin rrs 1401a > g 3/5 (60.0) 531/669 (79.4)
Streptomycin rrs 517c > t 3/42 (7.1) 57/1408 (4.1)
Table 2. High frequency drug resistance mutations. Mutations have been ordered by frequency. *The number 
of strains in this study predicted to be resistant by TB-Profiler software; **the number of strains in the global 
dataset (N > 18k)14 predicted to be resistant by TB-Profiler.
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123 Pakistan isolates and using an established cut-off of <10 mutation differences18 (Supplementary Fig. 2). Eight 
clusters were found, with a maximum size of three isolates. Of these eight clusters, four contained only MDR-TB 
strains, three only XDR-TB strains, and one both MDR-TB and XDR-TB strains. Five clusters belonged to lineage 
3, two to lineage 4, and one to lineage 1. Three of the clusters (the two lineage 4 clusters and a lineage 3 clus-
ter) involved isolates from Khyber Pakhtunkhwa province. Overall, these data suggest ongoing transmission of 
MDR-TB and XDR-TB in Pakistan.
Discussion
WGS is being used increasingly as a tool to assist epidemiological investigations and clinical and control program 
decision making in infectious diseases. However, most applications of WGS take place in developed countries, 
where the bacterial disease burden tends to be lower. Our study is the largest WGS analysis of drug resistant M. 
tuberculosis isolates from a high-burden TB region in Pakistan. In particular, the isolates were collected in Khyber 
Pakhtunkhwa province in North West Pakistan, a region that has been affected by recent armed conflict, social 
upheaval and refugee migration, and where operating an effective public health surveillance program has been 
difficult. CAS/Delhi was the most predominant strain-type identified in our analysis, and this is consistent with 
previous reports of lineage 3 strains dominating in South Asian populations12,15,33,34. The Beijing strain-type (lin-
eage 2) was present in our study (11%), and although absent from previous WGS studies in Pakistan12, studies 
using spoligotyping have observed this strain-type in Pakistan before (e.g. 6% in33). It is unclear if the differences 
in the Beijing frequencies are due to the effects of increased prevalence, isolate selection, or geographical region. 
In general, Beijing strains are highly virulent and mobile, and their presence in Pakistan (and likely Afghanistan) 
is a concern for public health surveillance. Interestingly, in pre-MDR-TB isolates, the presence of rifampicin 
resistance mutations was more common than isoniazid resistance conferring mutations. This observation poten-
tially indicates that resistance to rifampicin arises before isoniazid in this region, making this setting unique35. 
The high levels of fluoroquinolone (particularly ofloxacin) resistance in Pakistan have been observed by others2. 
This resistance, in some cases without evidence of rifampicin or isoniazid resistance, is worrisome and may be due 
to extensive and unregulated use of fluoroquinolones2.
The most frequent drug resistance conferring mutations identified in this study were already known, includ-
ing in katG (e.g. S315T) and Rv1482c–fabG1 intergenic region for isoniazid, rpoB (e.g. S450L and others in the 
RRDR) for rifampicin, embB (e.g. M306) for ethambutol, gyrA (e.g. D94) for fluoroquinolones, rrs (e.g. 1401a > g) 
for aminoglycosides, and rpsL, rrs and giB for streptomycin. The similarity of mutations observed and their fre-
quency with previous Pakistan XDR-TB WGS data19 and global collections9,14 suggests that extensions of line 
probe assays and genotyping arrays to account for these mutations may be useful for disease control. However, 
we did identify novel potential resistance conferring mutations, including polymorphisms in katG (isoniazid), 
ethA (ethionamide), gyrA and gyrA (fluoroquinolones), and pncA (pyrazinamide). These mutations should be 
investigated and validated experimentally to determine their impact on drug minimum inhibitory concentrations 
and regimen efficacy. Our analysis has also revealed the potential transmission of drug resistant M. tuberculosis 
in Pakistan. However, a larger sample size and denser sampling frame will be required to fully characterize the 
degree of XDR-/MDR-TB transmission alongside genetic and non-genetic risk factors.
Overall, our work reveals the utility of WGS for the prediction of antimicrobial drug resistance, epidemiology 
and control activities in the Pakistan setting. The WGS data generated will serve as a baseline reference for future 
TB clinical, surveillance and control activities in Pakistan and the wider region.
conclusion
The application of WGS for TB clinical management and disease control will have the greatest benefit in complex 
community outbreaks in endemic regions, where epidemiological data availability may be sparse. Our study in 
the Khyber Pakhtunkhwa province in Pakistan has provided a baseline characterization of circulating known and 
putative drug resistance mutations, and identified potential MDR-TB transmission chains. These insights will 
assist future proactive TB patient management, and the deployment of anti-TB drug regimens and surveillance 
activities.
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The accession codes for the raw sequence data are available in Supplementary Table 2.
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